Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy

References

• Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19. N Engl J Med. 2021;384(23):2259–6. doi:10.1056/NEJMc2103916.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A. Humoral immune response after different SARS-CoV-2 vaccination regimens. BMC Med. 2022;20:31. doi:10.1186/s12916-021-02231-x.
   PubMed Web of Science ®Google Scholar
• Ng DL, Goldgof GM, Shy BR, Levine AG, Balcerek J, Bapat SP, Prostko J, Rodgers M, Coller K, Pearce S, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nat Commun. 2020;11(1):4698. doi:10.1038/s41467-020-18468-8.
   PubMed Web of Science ®Google Scholar
• Eyre DW, Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, et al. Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. BMC Infect Dis. 2021;21(1):187. doi:10.1186/s12879-021-05878-2.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23. doi:10.1056/NEJMoa2101765.
   PubMed Web of Science ®Google Scholar
• Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–62. doi:10.1056/NEJMc2108861.
   PubMed Web of Science ®Google Scholar
• Narasimhan M, Mahimainathan L, Clark AE, Usmani A, Cao J, Araj E, Torres F, Sarode R, Kaza V, Lacelle C, et al. Serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines. Vaccines (Basel). 2021;9(7). doi:10.3390/vaccines9070708.
   Web of Science ®Google Scholar
• Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L, Martzloff J, Perrin P, Moulin B, Fafi-Kremer S, et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021;99(6):1487–89. doi:10.1016/j.kint.2021.03.014.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:10.1016/S1473-3099(20)30831-8.
   PubMed Web of Science ®Google Scholar
• Saeed U, Uppal SR, Piracha ZZ, Uppal R. SARS-CoV-2 spike antibody levels trend among Sinopharm vaccinated people. Iran J Public Health. 2021;50(7):1486–87. doi:10.18502/ijph.v50i7.6640.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78. doi:10.1016/j.ejphar.2014.07.025.
   PubMed Web of Science ®Google Scholar
• LLC WCC. 2022. Cisplatin: package insert. https://www.accessdatafdagov/drugsatfda_docs/label/2019/018057s089lblpdf.
   Google Scholar
• Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in our understanding of the molecular mechanisms of action of Cisplatin in cancer therapy. J Exp Pharmacol. 2021;13:303–28. doi:10.2147/JEP.S267383.
   PubMedGoogle Scholar
• Dezsi L, Meszaros T, Kozma TG, Velkei M, Olah C, Szabo M, Patko Z, Fulop GF, Hennies M, Szebeni M, et al. A naturally hypersensitive porcine model may help understanding the mechanism of COVID-19 vaccine-induced (pseudo)allergic reactions: complement activation as a possible contributing factor. Geroscience. 2022;44:597–618. doi:10.1007/s11357-021-00495-y.
   PubMed Web of Science ®Google Scholar
• Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Dobrovolskaia MA, Crommelin DJA. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nat Nanotechnol. 2022;17:337–46. doi:10.1038/s41565-022-01071-x.
   PubMed Web of Science ®Google Scholar
• Kozma TG, Meszaros T, Berenyi P, Facsko R, Patko Z, Olah C, Nagy A, Fulop G, Glatter KA, Radovits T, et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions and immunogenicity of PEG-containing Covid-19. medrxiv.Org/cgi/content/short/2022.10.03.22280227v1. doi:10.1101/2022.10.03.22280227
   Google Scholar
• Senti ME, de Jongh Ca, Dijkxhoorn K, Verhoef JJF, Szebeni J, Storm G. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J Controlled Release. 2021;341:475–86. doi:10.1016/j.jconrel.2021.11.042.
   PubMed Web of Science ®Google Scholar
• Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA. To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022;180:114079. doi:10.1016/j.addr.2021.114079.
   PubMed Web of Science ®Google Scholar
• Noda K, Matsuda K, Yagishita S, Maeda K, Akiyama Y, Terada-Hirashima J, Matsushita H, Iwata S, Yamashita K, Atarashi Y, et al. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci Rep. 2021;11(1):5198. doi:10.1038/s41598-021-84387-3.
   PubMed Web of Science ®Google Scholar
• Abbot. SARS-COV-2 immunoassays; 2022. https://wwwcorelaboratoryabbott/int/en/offerings/segments/infectious-disease/sars-cov-2-.
   Google Scholar
• Neumann F, Rose R, Rompke J, Grobe O, Lorentz T, Fickenscher H, Krumbholz A. Development of SARS-CoV-2 specific IgG and virus-neutralizing antibodies after infection with variants of concern or vaccination. Vaccines (Basel). 2021;9(7). doi:10.3390/vaccines9070700.
   Web of Science ®Google Scholar
• Martinez-Gallo M, Esperalba J, Pujol-Borrell R, Sanda V, Arrese-Munoz I, Fernandez-NavalC, Anton A, Cardona V, Labrador-Horrillo M, Pumarola T, et al. Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. Med Clin (Barc). 2021;159(3): 116–123.doi:10.1016/j.medcli.2021.09.013.
   PubMed Web of Science ®Google Scholar
• Qiagen. Quantiferon RUO; 2022. https://wwwqiagencom/us/products/diagnostics-and-clinical-research/infectious-disease/quantiferon-sars-cov-2-ruo/.
   Google Scholar
• Sinkovits G, Mezo B, Reti M, Muller V, Ivanyi Z, Gal J, Gopcsa L, Remenyi P, Szathmary B, Lakatos B, et al. Complement overactivation and consumption predicts in-hospital mortality in SARS-CoV-2 infection. Front Immunol. 2021;12:663187. doi:10.3389/fimmu.2021.663187.
   PubMed Web of Science ®Google Scholar
• Andreano E, Nicastri E, Paciello I, Pileri P, Manganaro N, Piccini G, Manenti A, Pantano E, Kabanova A, Troisi M, et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021;184(7):1821–35 e16. doi:10.1016/j.cell.2021.02.035.
   PubMed Web of Science ®Google Scholar
• Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, Wolzt M, Wagner OF, Binder CJ, Haslacher H. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiol Spectr. 2021;9(1):e0024721. doi:10.1128/Spectrum.00247-21.
   PubMed Web of Science ®Google Scholar
• Van Praet JT, Vandecasteele S, De Roo A, De Vriese AS, Reynders M. Humoral and cellular immunogenicity of the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in nursing home residents. Clin Infect Dis. 2021;73(11):2145–47. doi:10.1093/cid/ciab300.
   PubMed Web of Science ®Google Scholar
• Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020;93:250–56. doi:10.1002/jmv.26232.
   PubMed Web of Science ®Google Scholar
• Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine storm: the anger of inflammation. Cytokine. 2020;133:155151. doi:10.1016/j.cyto.2020.155151.
   PubMed Web of Science ®Google Scholar
• Kozma GT, Meszaros T, Bakos T, Hennies M, Bencze D, Uzonyi B, Gyorffy B, Cedrone E, Dobrovolskaia MA, Jozsi M, et al. Mini-factor H modulates complement-dependent IL-6 and IL-10 release in an immune cell culture (PBMC) model: potential benefits against cytokine storm. Front Immunol. 2021;12:642860. doi:10.3389/fimmu.2021.642860.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Rubin L, Peng T, Liu L, Xing X, Lazarovici P, Zheng W. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int J Biol Sci. 2022;18(2):459–72. doi:10.7150/ijbs.59272.
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Shimizu T, Ishida T. PEGylation and anti-PEG antibodies. In: Engineering of biomaterials for drug delivery systems: beyond polyethylene glycol. Woodhead Publishing Series in Biomaterials; 2018. p. 51–68. doi:10.1016/B978-0-08-101750-0.00003-9.
   Google Scholar
• Shimizu T, Abu Lila AS, Awata M, Kubo Y, Mima Y, Hashimoto Y, Ando H, Okuhira K, Ishima Y, Ishida T. A cell assay for detecting anti-PEG immune response against PEG-modified therapeutics. Pharm Res. 2018;35(11):223. doi:10.1007/s11095-018-2505-3.
   PubMed Web of Science ®Google Scholar
• CDC. Interim considerations: preparing for the potential management of anaphylaxis at COVID-19 vaccination sites summary. CDC; 2020. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/anaphylaxis-management.pdf.
   Google Scholar
• Banerji A, Wickner PG, Saff R, Stone CA Jr., Robinson LB, Long AA, Wolfson AR, Williams P, Khan DA, Phillips E, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2020;9:1423–37. doi:10.1016/j.jaip.2020.12.047.
   PubMed Web of Science ®Google Scholar
• Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anesthesia. 2020;126:e106–08. doi:10.1016/j.bja.2020.12.020.
   PubMed Web of Science ®Google Scholar
• Risma KA, Edwards KM, Hummell DS, Little FF, Norton AE, Stallings A, Wood RA, Milner JD. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021;147:2075–82.e2. doi:10.1016/j.jaci.2021.04.002.
   PubMedGoogle Scholar
• Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021;325:780. doi:10.1001/jama.2021.0600.
   PubMed Web of Science ®Google Scholar
• Team CC-R, Food, Drug A. Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125–29. doi:10.15585/mmwr.mm7004e1.
   PubMed Web of Science ®Google Scholar
• Vrieze J. Suspicions grow that nanoparticles in Pfizer’s COVID-19 vaccine trigger rare allergic reactions. Science. 2020. https://www.sciencemag.org/news/2020/12/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions.
   PubMedGoogle Scholar
• Ju Y, Lee SW, Kelly HG, Pilkington EH, Wragg KM, Subbarao K, Nguyen THO, Rowntree LC, Allen LF, Bond K, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. medRxiv 2022. doi:10.1101/2022.01.08.22268953.
   Google Scholar
• Ichihara M, Shimizu T, Imoto A, Hashiguchi Y, Uehara Y, Ishida T, Kiwada H. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics. 2010;3(1):1–11. doi:10.3390/pharmaceutics3010001.
   PubMedGoogle Scholar
• Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. Pegylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349–55. doi:10.1016/j.jconrel.2007.05.015.
   PubMed Web of Science ®Google Scholar
• Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H, Oku N. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm. 2010;392(1–2):218–23. doi:10.1016/j.ijpharm.2010.03.022.
   PubMedGoogle Scholar
• Shimizu T, Ishida T, Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology. 2013;218(5):725–32. doi:10.1016/j.imbio.2012.08.274.
   PubMed Web of Science ®Google Scholar
• Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature. 2021;596(7871):276–80. doi:10.1038/s41586-021-03777-9.
   PubMed Web of Science ®Google Scholar